NCT01541098
Withdrawn
Phase 2
A Phase II Clinical Study of Lyophilized Plasma in Patients on Warfarin
HemCon Medical Technologies, Inc0 sitesJanuary 2015
ConditionsAnticoagulant Therapy
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Anticoagulant Therapy
- Sponsor
- HemCon Medical Technologies, Inc
- Primary Endpoint
- Assess and Compare Adverse Events
- Status
- Withdrawn
- Last Updated
- 11 years ago
Overview
Brief Summary
This is a multi center, phase 2 randomized controlled study to determine the effect of lyophilized plasma in patients on warfarin therapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Assess and Compare Adverse Events
Time Frame: Duration of Study (Less than or equal to 72 hours)
The primary safety objective is to assess the adverse events after infusion of lyophilized plasma compared to control.
Similar Trials
Withdrawn
Phase 2
Clinical Study of Lyophilized Plasma in Patients With Liver DiseaseLiver DiseaseNCT01547078HemCon Medical Technologies, Inc
Completed
Phase 2
Lipid Infusion in Dialysis Patients With EndotoxemiaFatigueEnd Stage Renal Disease (ESRD)NCT00506454Sepsicure22
Recruiting
Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersGastric CancerColorectal CancerPancreatic CancerSarcomaMesotheliomaNeuroendocrine TumorsSquamous Cell CancerMerkel Cell CarcinomaMismatch Repair DeficiencyMicrosatellite InstabilityNCT03935893Udai Kammula240
Completed
Phase 2
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:Locally Advanced Pancreatic Carcinoma(LAPC)NCT03861702Nelson Yee28
Recruiting
Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal MelanomaUveal NeoplasmsMelanoma, UvealNCT03467516Udai Kammula47